Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
11 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
27 Feb 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
8-K
Other Events
21 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
2 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
2 Aug 23
8-K
Entry into a Material Definitive Agreement
18 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
8 May 23
DEF 14A
Definitive proxy
1 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
8-K
Other Events
13 Mar 23
10-K
2022 FY
Annual report
27 Feb 23
8-K
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
27 Feb 23
S-8
Registration of securities for employees
6 Feb 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
2 Nov 22
8-K
Departure of Directors or Certain Officers
28 Oct 22
8-K
Departure of Directors or Certain Officers
13 Oct 22
S-8
Registration of securities for employees
8 Aug 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K
Departure of Directors or Certain Officers
10 Jun 22
S-3ASR
Automatic shelf registration
25 May 22
DEFR14A
Revised proxy
13 May 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
4 May 22
CT ORDER
Confidential treatment order
4 May 22
DEF 14A
Definitive proxy
29 Apr 22
8-K
Departure of Directors or Certain Officers
8 Apr 22
10-K
2021 FY
Annual report
1 Mar 22
8-K
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
28 Feb 22
8-K
Acadia Pharmaceuticals Announces Plan for a Resubmission of its
20 Dec 21
8-K
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice
14 Dec 21
Latest ownership filings
3
Elizabeth H.Z. Thompson
15 Apr 24
4
STEPHEN DAVIS
9 Apr 24
4
Brendan Teehan
9 Apr 24
4
James Kihara
9 Apr 24
4
Mark C. Schneyer
9 Apr 24
4
James Kihara
27 Mar 24
4
Brendan Teehan
27 Mar 24
4
STEPHEN DAVIS
27 Mar 24
4
Mark C. Schneyer
27 Mar 24
4
Mark C. Schneyer
27 Feb 24
4
Brendan Teehan
27 Feb 24
4
James Kihara
27 Feb 24
4
STEPHEN DAVIS
27 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Jennifer J Rhodes
8 Feb 24
3
Jennifer J Rhodes
8 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
STEPHEN DAVIS
9 Jan 24
4
Brendan Teehan
9 Jan 24
4
AUSTIN D. KIM
9 Jan 24
4
James Kihara
15 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
4
ELIZABETH A. GAROFALO
28 Nov 23
4
Brendan Teehan
21 Nov 23
4
Mark C. Schneyer
21 Nov 23
4
James Kihara
21 Nov 23
4
Adora Ndu
16 Oct 23
4
AUSTIN D. KIM
6 Oct 23
4
STEPHEN DAVIS
6 Oct 23
4
James Kihara
19 Sep 23
144
Notice of proposed sale of securities
15 Sep 23
4
Mark C. Schneyer
23 Aug 23
144
Notice of proposed sale of securities
21 Aug 23
4
STEPHEN DAVIS
18 Jul 23
144
Notice of proposed sale of securities
14 Jul 23
4
STEPHEN DAVIS
13 Jul 23
144
Notice of proposed sale of securities
13 Jul 23
4
James Kihara
16 Jun 23